(Inotuzumab)Biosimilar Reference Antibody-GS40339

货号：GS40339

Inotuzumab ozogamicin (brand name Besponsa®) is an antibody-drug conjugate (ADC) approved for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in adults. It consists of a humanized monoclonal IgG4 antibody targeting CD22, linked to the potent cytotoxic agent calicheamicin via an acid-labile linker. Inotuzumab ozogamicin functions as a targeted chemotherapy agent. The antibody component binds specifically to CD22 on the surface of leukemic blasts. Upon binding, the ADC is rapidly internalized. Within the acidic environment of the lysosome, the linker is cleaved, releasing the calicheamicin payload. Calicheamicin causes double-strand DNA breaks, leading to cell cycle arrest and apoptosis, thereby selectively killing CD22-positive leukemia cells.